Low-renin hypertension with relative aldosterone excess is associated with impaired NO-mediated vasodilation

Hypertension

Volumn 46, Issue 4, 2005, Pages 707-713

  Duffy, Stephen J ^b   Biegelsen, Elizabeth S ^a   Eberhardt, Robert T ^a   Kahn, David F ^a   Kingwell, Bronwyn A ^b   Vita, Joseph A ^a,c  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ALFRED HOSPITAL   (Australia)

^c BOSTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Aldosterone; Blood flow; Endothelium; Mineralocorticoids; Renin

Indexed keywords

ALDOSTERONE; METHACHOLINE; NITROPRUSSIDE SODIUM; RENIN; VERAPAMIL;

ADULT; ALDOSTERONE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; EVALUATION; FEMALE; FOREARM BLOOD FLOW; HUMAN; HYPERTENSION; MALE; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESISTANCE BLOOD VESSEL; VASODILATATION; VEIN OCCLUSION PLETHYSMOGRAPHY;

ADULT; AGED; ALDOSTERONE; CASE-CONTROL STUDIES; FEMALE; FOREARM; HUMANS; HYPERALDOSTERONISM; HYPERTENSION; MALE; MIDDLE AGED; NITRIC OXIDE; PROSPECTIVE STUDIES; RENIN; VASCULAR RESISTANCE; VASODILATION;

EID: 31944444788     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000184231.84465.62     Document Type: Article

References (44)

1. Brunner HR, Laragh JH, Baer L, Newton MA, Goodwin FT, Krakoff LR, Bard RH, Buhler FR. Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med. 1972;286:441-449.
2. Weinberger MH, Miller JZ, Luft FC, Grim CE, Fineberg NS. Definitions and characteristics of sodium sensitivity and blood pressure resistance. Hypertension. 1986;8:II127-II134.
3. Campese VM. Salt sensitivity in hypertension. Renal and cardiovascular implications. Hypertension. 1994;23:531-550.
4. Warnock DG. Low-renin and nonmodulating essential hypertension. Hypertension. 1999;34:395-397.
5. Conn JW, Cohen EL, Rovner DR, Nesbit RM. Normokalemic primary aldosteronism. A detectable cause of curable "essential" hypertension. J Am Med Assoc. 1965;193:200-206.
6. Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Rutherford JC. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol. 1994;21:315-318.
7. Lim PO, Struthers AD, MacDonald TM. The neurohormonal natural history of essential hypertension: towards primary or tertiary aldosteronism? J Hypertens. 2002;20:11-15.
8. Fritsch Neves M, Schiffrin EL. Aldosterone: a risk factor for vascular disease. Curr Hypertens Rep. 2003;5:59-65.
9. Alderman MH, Madhavan S, Ooi WL. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med. 1991;324:1098-1104.
10. Morimoto A, Uzu T, Fujii T, Nishimura M, Kuroda S, Nakamura S, Inenaga T, Kimura G. Sodium sensitivity and cardiovascular events in patients with essential hypertension. Lancet. 1997;350:1734-1737.
11. Weinberger MH, Fineberg NS, Fineberg SE, Weinberger M. Salt sensitivity, pulse pressure, and death in normal and hypertensive humans. Hypertension. 2001;37:429-432.
12. Meade TW, Imeson JD, Gordon D, Peart WS. The epidemiology of plasma renin. Clin Sci (Lond). 1983;64:273-280.
13. Münzel T, Keaney JF Jr. Are ACE-inhibitors a "magic bullet" against oxidative stress? Circulation. 2001;104:1571-1574.
14. Schiffrin EL. Vascular and cardiac benefits of angiotensin receptor blockers. Am J Med. 2002;113:409-418.
15. Perticone F, Ceravolo R, Pujia A, Ventura G, Iacopino S, Scozzafava A, Ferraro A, Chello M, Mastroroberto P, Verdecchia P, Schillaci G. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation. 2001;104:191-196.
16. Modena MG, Bonetti L, Coppi F, Bursi F, Rossi R. Prognostic role of reversible endothelial dysfunction in hypertensive postmenopausal women. J Am Coll Cardiol. 2002;40:505-510.
17. Rajagopalan S, Kurz S, Münzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. J Clin Invest. 1996;97:1916-1923.
18. Virdis A, Neves MF, Amiri F, Viel E, Touyz RM, Schiffrin EL. Spironolactone improves angiotensin-induced vascular changes and oxidative stress. Hypertension. 2002;40:504-510.
19. Somers MJ, Mavromatis K, Galis ZS, Harrison DG. Vascular superoxide production and vasomotor function in hypertension induced by deoxycorticosterone acetate-salt. Circulation. 2000;101:1722-1728.
20. Taddei S, Virdis A, Mattei P, Salvetti A. Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension. 1993;21:929-933.
21. Nishizaka MK, Zaman MA, Green SA, Renfroe KY, Calhoun DA. Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism. Circulation. 2004;109:2857-2861.
22. Farquharson CA, Struthers AD. Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy. Clin Sci (Lond). 2002;103:425-431.
23. Taddei S, Virdis A, Ghiadoni L, Sudano I, Salvetti A. Effects of antihypertensive drugs on endothelial dysfunction: clinical implications. Drugs. 2002;62:265-284.
24. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel Spaceiiiqq). J Am Med Assoc. 2001;285:2486-2497.
25. Sherman DL, Keaney JF Jr, Biegelsen ES, Duffy SJ, Coffman JD, Vita JA. Pharmacological concentrations of ascorbic acid are required for the beneficial effects on endothelial vasomotor function in hypertension. Hypertension. 2000;35:936-941.
26. Duffy SJ, Biegelsen ES, Holbrook M, Russell JD, Gokce N, Keaney JF, Jr., Vita JA. Iron chelation improves endothelial function in patients with coronary artery disease. Circulation. 2001;103:2799-2804.
27. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
28. Stowasser M. New perspectives on the role of aldosterone excess in cardiovascular disease. Clin Exp Pharmacol Physiol. 2001;28:783-791.
29. Panza JA, Quyyumi AA, Brush JE, Epstein SE. Abnormal endothelium- dependent vascular relaxation in patients with essential hypertension. N Engl J Med. 1990;323:22-27.
30. Reaven GM, Oithell H, Landsberg L. Hypertension and associated metabolic abnormalities-The role of insulin resistance and the sympathoadrenal system. N Engl J Med. 1996;334:374-381.
31. Perticone F, Maio R, Tripepi G, Zoccali C. Endothelial dysfunction and mild renal insufficiency in essential hypertension. Circulation. 2004;110:821-825.
32. Bragulat E, de la SA, Antonio MT, Coca A. Endothelial dysfunction in salt-sensitive essential hypertension. Hypertension. 2001;37:444-448.
33. Omland T, Johnson W, Gordon MB, Creager MA. Endothelial function during stimulation of renin-angiotensin system by low-sodium diet in humans. Am J Physiol Heart Circ Physiol. 2001;280:H2248-H2254.
34. Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation. 2000;101:594-597.
35. Li L, Fink GD, Watts SW, Northcott CA, Galligan JJ, Pagano PJ, Chen AF. Endothelin-1 increases vascular superoxide via endothelin(A)-NADPH oxidase pathway in low-renin hypertension. Circulation. 2003;107:1053-1058.
36. Zhou MS, Adam AG, Jaimes EA, Raij L. In salt-sensitive hypertension, increased superoxide production is linked to functional upregulation of angiotensin II. Hypertension. 2003;42:945-951.
37. Beswick RA, Dorrance AM, Leite R, Webb RC. NADH/NADPH oxidase and enhanced superoxide production in the mineralocorticoid hypertensive rat. Hypertension. 2001;38:1107-1111.
38. Ergul A. Hypertension in black patients: an emerging role of the endothelin system in salt-sensitive hypertension. Hypertension. 2000;36:62-67.
39. Schiffrin EL, Touyz RM. From bedside to bench to bedside: role of renin-angiotensin-aldosterone system in remodeling of resistance arteries in hypertension. Am J Physiol Heart Circ Physiol. 2004;287:H435-H446.
40. Taddei S, Virdis A, Mattei P, Ghiadoni L, Gennari A, Fasolo CB, Sudano I, Salvetti A. Aging and endothelial function in normotensive subjects and patients with essential hypertension. Circulation. 1995;91:1981-1987.
41. Widlansky ME, Gokce N, Keaney JF Jr, Vita JA. The clinical implications of endothelial dysfunction. J Am Coll Cardiol. 2003;42:1149-1160.
42. Takimoto E, Champion HC, Li M, Belardi D, Ren S, Rodriguez ER, Bedja D, Gabrielson KL, Wang Y, Kass DA Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med. 2005.
43. Lim PO, Jung RT, MacDonald TM. Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study. Br J Clin Pharmacol. 1999;48:756-760.
44. Krum H, Nolly H, Workman D, He W, Roniker B, Krause S, Fakouhi K. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension. 2002;40:117-123.